Share-based Payment Arrangement, Expense of Blueprint Medicines Corp from 31 Dec 2013 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Blueprint Medicines Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 31 Mar 2025.
  • Blueprint Medicines Corp Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $29,056,000, a 20% increase year-over-year.
  • Blueprint Medicines Corp Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $113,742,000, a 21% increase year-over-year.
  • Blueprint Medicines Corp annual Share-based Payment Arrangement, Expense for 2024 was $108,911,000, a 18% increase from 2023.
  • Blueprint Medicines Corp annual Share-based Payment Arrangement, Expense for 2023 was $92,672,000, a 6.4% decline from 2022.
  • Blueprint Medicines Corp annual Share-based Payment Arrangement, Expense for 2022 was $98,971,000, a 8% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Blueprint Medicines Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $113,742,000 $29,056,000 +$4,831,000 +20% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $108,911,000 $28,382,000 +$5,798,000 +26% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $103,113,000 $28,282,000 +$5,211,000 +23% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 $97,902,000 $28,022,000 +$4,201,000 +18% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $93,701,000 $24,225,000 +$1,029,000 +4.4% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $92,672,000 $22,584,000 -$3,532,000 -14% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $96,204,000 $23,071,000 -$1,038,000 -4.3% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $97,242,000 $23,821,000 -$1,526,000 -6% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $98,768,000 $23,196,000 -$203,000 -0.87% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $98,971,000 $26,116,000 +$3,435,000 +15% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $95,536,000 $24,109,000 +$151,000 +0.63% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023 2023 Q3
Q2 2022 $95,385,000 $25,347,000 +$1,040,000 +4.3% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $94,345,000 $23,399,000 +$2,715,000 +13% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $91,630,000 $22,681,000 +$3,177,000 +16% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $88,453,000 $23,958,000 +$4,323,000 +22% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $84,130,000 $24,307,000 +$4,779,000 +24% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $79,351,000 $20,684,000 +$3,825,000 +23% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $75,526,000 $19,504,000 +$3,805,000 +24% 01 Oct 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
Q3 2020 $71,721,000 $19,635,000 +$4,642,000 +31% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $67,079,000 $19,528,000 +$5,862,000 +43% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $61,217,000 $16,859,000 +$6,564,000 +64% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $54,653,000 $15,699,000 +$6,866,000 +78% 01 Oct 2019 31 Dec 2019 10-K 17 Feb 2022 2021 FY
Q3 2019 $47,787,000 $14,993,000 +$6,602,000 +79% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $41,185,000 $13,666,000 +$5,905,000 +76% 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 $35,280,000 $10,295,000 +$4,746,000 +86% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $30,534,000 $8,833,000 +$5,128,000 +138% 01 Oct 2018 31 Dec 2018 10-K 17 Feb 2021 2020 FY
Q3 2018 $25,406,000 $8,391,000 +$4,792,000 +133% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $20,614,000 $7,761,000 +$4,782,000 +161% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $15,832,000 $5,549,000 +$3,309,000 +148% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $12,523,000 $3,705,000 +$2,059,000 +125% 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
Q3 2017 $10,464,000 $3,599,000 +$1,694,000 +89% 01 Jul 2017 30 Sep 2017 10-Q 30 Oct 2018 2018 Q3
Q2 2017 $8,770,000 $2,979,000 +$1,492,000 +100% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $7,278,000 $2,240,000 +$1,138,000 +103% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2017 2017 Q1
Q4 2016 $6,140,000 $1,646,000 +$451,000 +38% 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $5,689,000 $1,905,000 +$934,000 +96% 01 Jul 2016 30 Sep 2016 10-Q 31 Oct 2017 2017 Q3
Q2 2016 $4,755,000 $1,487,000 -$687,000 -32% 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017 2017 Q2
Q1 2016 $5,442,000 $1,102,000 +$262,000 +31% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $5,180,000 $1,195,000 -$105,000 -8.1% 01 Oct 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
Q3 2015 $5,285,000 $971,000 +$404,000 +71% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $4,881,000 $2,174,000 +$1,982,000 +1032% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $2,899,000 $840,000 +$573,000 +215% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $2,326,000 $1,300,000 01 Oct 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
Q3 2014 $567,000 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $192,000 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $267,000 01 Jan 2014 31 Mar 2014 10-Q 11 Jun 2015 2015 Q1

Blueprint Medicines Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $108,911,000 +$16,239,000 +18% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $92,672,000 -$6,299,000 -6.4% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $98,971,000 +$7,341,000 +8% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $91,630,000 +$16,104,000 +21% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $75,526,000 +$20,873,000 +38% 01 Jan 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
2019 $54,653,000 +$24,119,000 +79% 01 Jan 2019 31 Dec 2019 10-K 17 Feb 2022 2021 FY
2018 $30,534,000 +$18,011,000 +144% 01 Jan 2018 31 Dec 2018 10-K 17 Feb 2021 2020 FY
2017 $12,523,000 +$6,383,000 +104% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $6,140,000 +$960,000 +19% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
2015 $5,180,000 +$2,854,000 +123% 01 Jan 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
2014 $2,326,000 +$1,975,000 +563% 01 Jan 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
2013 $351,000 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.